^
Association details:
| Biomarker: | CCND1 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug Class: | Aromatase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer
Published date:
09/02/2020
Excerpt:
CCND1 gene amplification was associated with shorter progression-free survival (PFS) in patients receiving aromatase inhibitors (AI) [16.0 months vs. 32.4 months, HR = 3.16 (95% CI 1.26-7.93), p = 0.014]. Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
DOI:
10.1007/s12094-020-02481-w
